A 30 Day Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for Percutaneous Coronary Intervention (PCI) (ATLANTIC)
A 30 Day International, Randomized, Parallel-group, Double-blind, Placebo-controlled Phase IV Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for PCI.
Sponsor: AstraZeneca
A PHASE4 clinical study on Myocardial Infarction and Segment Elevation Myocardial Infarction (STEMI), this trial is completed. The trial is conducted by AstraZeneca and has accumulated 11 data snapshots since 2011. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Dec 2021 — Jul 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Dec 2021 [monthly]
Completed PHASE4
▶ Show 6 earlier versions
-
Nov 2020 — Jan 2021 [monthly]
Completed PHASE4
-
Jun 2018 — Nov 2020 [monthly]
Completed PHASE4
-
May 2018 — Jun 2018 [monthly]
Completed PHASE4
-
Aug 2017 — May 2018 [monthly]
Completed PHASE4
-
Feb 2017 — Aug 2017 [monthly]
Completed PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE4
First recorded
Sep 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
's-Hertogenbosch, Netherlands , A Coruña, Spain , Aalborg, Denmark , Aarhus, Denmark , Algiers, Algeria , Alicante, Spain , Alkmaar, Netherlands , Arezzo, Italy , Arnhem, Netherlands , Ascoli Piceno, Italy and 86 more locations